Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 6/2008

01.06.2008 | original paper

Surrogate Markers of Resectability in Patients Undergoing Exploration of Potentially Resectable Pancreatic Adenocarcinoma

verfasst von: S. L. Ong, G. Garcea, S. C. Thomasset, C. D. Mann, C. P. Neal, M. Abu Amara, A. R. Dennison, D. P. Berry

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Despite extensive preoperative staging, a significant number of pancreatic cancers are unresectable at surgical exploration. Patients undergoing pancreatic exploration with a view to resection were studied and comparisons are then made between those undergoing resection and a bypass procedure to identify surrogate markers of unresectability. One hundred thirteen consecutive patients underwent pancreatic exploration for head-of-pancreas (HOP) adenocarcinoma with curative intent. Fifty-five underwent pancreaticoduodenectomy and 58 underwent a bypass procedure. Student’s t test, receiver operator characteristics (ROC) and logistic regression were used to compare the predictive value of preoperative patient variables collected retrospectively. The bypass group had a significantly higher median CA19.9 than the resection group (P = 0.003). Platelet count and neutrophil–lymphocyte ratio (NLR) were also significantly different (P = 0.013 and P = 0.026, respectively). ROC analysis indicated that age ≤65, platelet count >297 × 109/l, CA19.9 ≤473 Ku/l, and CA19.9–bilirubin ratio were predictive variables for resectable disease. NLR and CA19.9–bilirubin ratio had specificity values of 92.9 and 97.0%, respectively. From logistic regression, a raised CA19.9 was found to be an independent risk factor for unresectable disease (P = 0.031). A significant proportion of patients with HOP adenocarcinoma are understaged preoperatively. Preoperative serology including platelet count, NLR, CA19.9, and CA19.9–bilirubin ratio may be used as additional discriminators of resectability particularly for high-risk patients.
Literatur
1.
2.
Zurück zum Zitat Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 1997;226:248–257.PubMedCrossRef Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 1997;226:248–257.PubMedCrossRef
3.
Zurück zum Zitat Garcea G, Dennison AR, Ong SL, Pattenden CJ, Neal CP, Sutton CD, Mann CD, Berry DP. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007;33:892–897.PubMed Garcea G, Dennison AR, Ong SL, Pattenden CJ, Neal CP, Sutton CD, Mann CD, Berry DP. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007;33:892–897.PubMed
4.
Zurück zum Zitat Zacharias T, Jaeck D, Oussoultzoglow E, Neuville A, Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007;11(3):350–356.PubMedCrossRef Zacharias T, Jaeck D, Oussoultzoglow E, Neuville A, Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007;11(3):350–356.PubMedCrossRef
5.
Zurück zum Zitat Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Gines MA, Real MI, Gilabert R, Quinto L, Trilla A, Feu F, Montanya X, Fernandez-Cruz L, Navarro S. Preoperative staging and tumor resectability assessment of pancreatic cancer: Prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging and angiography. Am J Gastroenterol 2004;99(3):492–501.PubMedCrossRef Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Gines MA, Real MI, Gilabert R, Quinto L, Trilla A, Feu F, Montanya X, Fernandez-Cruz L, Navarro S. Preoperative staging and tumor resectability assessment of pancreatic cancer: Prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging and angiography. Am J Gastroenterol 2004;99(3):492–501.PubMedCrossRef
6.
Zurück zum Zitat Camacho D, Reichenbach D, Guerr GD, Venema TL, Sweeney JF, Fisher WE. Value of laparoscopy in the staging of pancreatic cancer. JOP 2005;6(6):552–561.PubMed Camacho D, Reichenbach D, Guerr GD, Venema TL, Sweeney JF, Fisher WE. Value of laparoscopy in the staging of pancreatic cancer. JOP 2005;6(6):552–561.PubMed
7.
Zurück zum Zitat Long EE, Van Dam J, Weinstein S, Jeffrey B, Desser T, Norton JA. Computed tomography, endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancer. Surg Oncol 2005;14(2):105–113.PubMedCrossRef Long EE, Van Dam J, Weinstein S, Jeffrey B, Desser T, Norton JA. Computed tomography, endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancer. Surg Oncol 2005;14(2):105–113.PubMedCrossRef
8.
Zurück zum Zitat Kilic M, Gocmen E, Tez M, Ertan T, Keskek M, Koc M. Value of preoperative serum CA 19.9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006;49(4):241–244.PubMed Kilic M, Gocmen E, Tez M, Ertan T, Keskek M, Koc M. Value of preoperative serum CA 19.9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006;49(4):241–244.PubMed
9.
Zurück zum Zitat Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138(9):951–955.PubMedCrossRef Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138(9):951–955.PubMedCrossRef
10.
Zurück zum Zitat Karachristos A, Scarmeas N, Hoffman JP. CA19.9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005;9(9):1286–1292.PubMedCrossRef Karachristos A, Scarmeas N, Hoffman JP. CA19.9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005;9(9):1286–1292.PubMedCrossRef
11.
Zurück zum Zitat Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA19.9 levels in pancreatic adenocarcinoma. Ann Surg 1992;215(4):350–355.PubMedCrossRef Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA19.9 levels in pancreatic adenocarcinoma. Ann Surg 1992;215(4):350–355.PubMedCrossRef
12.
Zurück zum Zitat Lowe D, Lee J, Schade R, Chaudhary A. Patient with markedly elevated CA19.9 not associated with malignancy. South Med J 2006;99(3):306–308.PubMedCrossRef Lowe D, Lee J, Schade R, Chaudhary A. Patient with markedly elevated CA19.9 not associated with malignancy. South Med J 2006;99(3):306–308.PubMedCrossRef
13.
Zurück zum Zitat Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19.9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26(5):474–479.PubMedCrossRef Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19.9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26(5):474–479.PubMedCrossRef
14.
Zurück zum Zitat Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91(3):181–184.PubMedCrossRef Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91(3):181–184.PubMedCrossRef
15.
Zurück zum Zitat Cook EJ, Walsh SR, Farooq N, Alberts JC, Justin TA, Keeling NJ. Post-operative neutrophil–lymphocyte ratio predicts complications following colorectal surgery. Int J Surg 2007;5(1):27–30.PubMedCrossRef Cook EJ, Walsh SR, Farooq N, Alberts JC, Justin TA, Keeling NJ. Post-operative neutrophil–lymphocyte ratio predicts complications following colorectal surgery. Int J Surg 2007;5(1):27–30.PubMedCrossRef
16.
Zurück zum Zitat Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357(9255):539–545.PubMedCrossRef Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357(9255):539–545.PubMedCrossRef
17.
Zurück zum Zitat Coussen LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860–867.CrossRef Coussen LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860–867.CrossRef
18.
Zurück zum Zitat Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, Tsuji S, Kawaguchi M, Nakajima S, Kobayashi H, Masui T, Imamura M. Interleukin-6 inhibits radiation-induced apoptosis in pancreatic cancer cells. Anticancer Res 2001;21:2449–2456.PubMed Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, Tsuji S, Kawaguchi M, Nakajima S, Kobayashi H, Masui T, Imamura M. Interleukin-6 inhibits radiation-induced apoptosis in pancreatic cancer cells. Anticancer Res 2001;21:2449–2456.PubMed
19.
Zurück zum Zitat Hasselgren PO, Fischer E. Muscle cachexia: Current concept of intracellular mechanism and molecular regulation. Ann Surg 2001;233(1):9–17.PubMedCrossRef Hasselgren PO, Fischer E. Muscle cachexia: Current concept of intracellular mechanism and molecular regulation. Ann Surg 2001;233(1):9–17.PubMedCrossRef
20.
Zurück zum Zitat Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005;189(3):278–282.PubMedCrossRef Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005;189(3):278–282.PubMedCrossRef
21.
Zurück zum Zitat Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas 2004;29(2):132–140.PubMedCrossRef Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas 2004;29(2):132–140.PubMedCrossRef
22.
Zurück zum Zitat Schwarz RE, Keny H. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001;48(41):1493–1498.PubMed Schwarz RE, Keny H. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001;48(41):1493–1498.PubMed
23.
Zurück zum Zitat House MG, Yeo CJ, Cameron JL, Campbell KA, Schulich RD, Leach SD, Hruban RH, Horton KM, Fishman EK, Lillemoe KD. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 2004;8(3):280–288.PubMedCrossRef House MG, Yeo CJ, Cameron JL, Campbell KA, Schulich RD, Leach SD, Hruban RH, Horton KM, Fishman EK, Lillemoe KD. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 2004;8(3):280–288.PubMedCrossRef
24.
Zurück zum Zitat Maemura K, Takao S, Shinchi H, Noma H, Mataki Y, Kurahara H, Jinnouchi S, Aikou T. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 2006;13(5):435–441.PubMedCrossRef Maemura K, Takao S, Shinchi H, Noma H, Mataki Y, Kurahara H, Jinnouchi S, Aikou T. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 2006;13(5):435–441.PubMedCrossRef
25.
Zurück zum Zitat Mortensen MB, Edwin B, Hunerbein M, Liedman B, Neilsen HO, Hovendal C. Impact of endoscopic ultrasonography (EUS) on surgical decision-making in upper gastrointestinal tract cancer: An international multicenter study. Surg Endosc 2007;21(3):431–438.PubMedCrossRef Mortensen MB, Edwin B, Hunerbein M, Liedman B, Neilsen HO, Hovendal C. Impact of endoscopic ultrasonography (EUS) on surgical decision-making in upper gastrointestinal tract cancer: An international multicenter study. Surg Endosc 2007;21(3):431–438.PubMedCrossRef
Metadaten
Titel
Surrogate Markers of Resectability in Patients Undergoing Exploration of Potentially Resectable Pancreatic Adenocarcinoma
verfasst von
S. L. Ong
G. Garcea
S. C. Thomasset
C. D. Mann
C. P. Neal
M. Abu Amara
A. R. Dennison
D. P. Berry
Publikationsdatum
01.06.2008
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 6/2008
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-007-0422-6

Weitere Artikel der Ausgabe 6/2008

Journal of Gastrointestinal Surgery 6/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.